By Editor , 10 September 2026
Sky Labs' CART Ring Hits 300,000 Prescriptions, Enters Korea BP Guidelines

Munich – September 09, 2026 -- Sky Labs presented new clinical data at ESC Congress 2026 showing its ring-shaped blood pressure monitor, CART, achieves an approximately 80% data-usability rate in continuous 24-hour monitoring of patients with atrial fibrillation, addressing a measurement gap left by traditional cuff-based devices in patients with irregular pulse or severe blood pressure fluctuations.

By Editor , 10 September 2026
Sky Labs' CART Ring Validated for AFib, Heart Failure BP Monitoring

Munich – September 09, 2026 -- Sky Labs unveiled new clinical data at ESC Congress 2026 showing its ring-shaped blood pressure monitor CART achieved an 80% data evaluability rate in 24-hour monitoring of patients with atrial fibrillation (AFib), addressing a gap where conventional cuffs struggle with irregular pulses.

By Editor , 10 September 2026
Sky Labs' CART Ring Shows 80% Data Accuracy in AFib, Heart Failure Trials

Munich – September 09, 2026 -- Sky Labs presented new clinical trial data for its ring-based blood pressure monitor, CART, at the ESC Congress 2026 in Munich on September 7, showing an 80% data evaluability rate in continuous monitoring of atrial fibrillation (AFib) patients and high correlation with standard ambulatory blood pressure monitoring (ABPM) in severe heart failure cases.

By Editor , 9 September 2026
ACG Delivers First 737-8 in New Trinity Airways Livery

Newport Beach, Calif. – September 08, 2026 -- Aviation Capital Group LLC (ACG) has delivered a new Boeing 737-8 to Trinity Airways, the South Korean carrier formerly known as T'way Air, marking the first aircraft to enter service in the airline's new Trinity Gray and Rose Gold livery.

Delivery marks third of seven aircraft under ACG-Trinity mandate

The jet is the third aircraft delivered by ACG to Trinity under a seven-aircraft Boeing 737-8 order, with the remaining four scheduled for delivery from ACG's orderbook by the end of 2026.

By Editor , 8 September 2026

Daejeon – – September 07, 2026 -- Alteogen Inc. (KOSDAQ: 196170) has signed an option and license agreement with Novartis worth up to US$3,223 million, granting the Swiss drugmaker rights to develop subcutaneous formulations for multiple Novartis products using Alteogen's ALT-B4 hyaluronidase.